CEL-SCI Corp
CVM
Market cap $20.1M

0.2548 USD

-0.0027

1.05%

At close Apr 17, 4:00 PM EDT

After hours

0.2575

+0.0027

1.06%

1 day

-1.05%

5 days

20.25%

1 month

-10.31%

3 months

-36.71%

6 months

-73.18%

Year to date

-38.59%

1 year

-83.01%

5 years

-97.67%

10 years

-98.90%

About: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Employees: 44

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,419 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

0.67% more ownership

Funds ownership: 9.72% [Q3] → 10.38% (+0.67%) [Q4]

8% less funds holding

Funds holding: 66 [Q3] → 61 (-5) [Q4]

53% less capital invested

Capital invested by funds: $6.32M [Q3] → $2.96M (-$3.36M) [Q4]

59% less call options, than puts

Call options by funds: $40K | Put options by funds: $98K

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CVM.

See Analyst Rankings

Financial journalist opinion

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--New study in the scientific journal “Cancer Cell” supports CEL-SCI's strategy to seek early approval for Multikine.

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $2.5 million offering .

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $2.5 million offering.

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Head and Neck Cancer Registration Study Protocol clears FDA review—in talks with potential partners Interested in commercialization of Multikine.

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows pre-surgical tumor elimination and regression in just 3 weeks.

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck cancer.

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $5 million offering.

CEL-SCI Announces Closing of $5 Million Offering

See News Rankings

Charts implemented using Lightweight Charts™